China Healthcare Weekly (July.28)- Ascentage Gets "A Big Gift", CR Boya Acquires Green Cross, Weigao
252 Views28 Jul 2024 13:43
We noticed some positive updates about Ascentage as competitors' products encountered challenges. China Resources Boya acquires Green Cross. Weigao's weak share price is related to its business model.
What is covered in the Full Insight:
- Ascentage Competitive Landscape
- China Resources Boya Acquisition
- Weigao's Performance
- Industry Viewpoints
- Market Review and Risk Disclosure
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Healthcare Weekly (Aug.4)- Taiji Group & China TCM, TCM Formula Granules VBP, Keymed's Trouble04 Aug 2024
- China Healthcare Weekly (July.28)- Ascentage Gets "A Big Gift", CR Boya Acquires Green Cross, Weigao28 Jul 2024
- CPMC Holdings (906.HK) Privatization Update - The Story Behind the Delay of Offer Document Despatch25 Jul 2024
- Legend Biotech (LEGN US) - A Takeover Offer?15 Jul 2024
- Ascentage Pharma (6855.HK) Signs $1.3B Deal with Takeda - Finally on the Right Path17 Jun 2024
x